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Anthracycline antibiotics, especially daunorubicin, are widely used for the treatment of acute 
myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). 
Although the efficacy of these drugs is high, treatment is still limited due to cardiotoxicity and 
tumor cell resistance to anthracyclines. 
Mechanisms that contribute to the formation of anthracycline resistance include metabolic 
biotransformation (reduction) to less efficient secondary alcohols. The reduction is calatyzed 
by carbonyl reducing enzymes belonging to aldo-keto reductase (AKR) and short chain 
dehydrogenase/reductase (SDR) superfamilies. 
The discovery of AKR and SDR inhibitors could help to overcome anthracycline resistance and 
also reduce cardiotoxicity caused by these drugs. 
The aim of the diploma thesis was to find out whether all-trans-retinoic acid, 
cyclophosphamide, cytarabine, cladribine and prednisolone are able to inhibit anthracycline 
reductases AKR1A1, AKR1B10, AKR1C3, AKR7A2 and CBR1. 
The methodology of the diploma thesis includes in vitro incubation of the enzymes with 
daunorubicin as substrate in sodiumphosphate buffer, isolation of daunorubicinol from the 
reaction mixture and measurement of its amount by high performance liquid chromatography 
(UHPLC). The amount of daunorubicinol determined by UHPLC is then used to calculate the 
specific activity. 
The most aktive inhibitors were all-trans-retinoic acid that decresed the activity of AKR1B10 
(IC50 = 74,5 µM) and AKR1C3 (IC50 = 1,2 µM) and prednisolone that decreased activity of 
AKR1C3 (IC50 = 57,6 µM). 
